

Fructosamine 3-Kinase in Erythrocytes for Myocardial Infarction Patients

Rafad R.S. Mohammed^{1*}, Tamara Sh. Abdulrahman²

¹Department of Chemistry, College of Science, University of Mosul, Mosul, Iraq.
Email: rafadsaadun2000@uomosul.edu.iq

²Department of Dentistry, Al-Noor University, Mosul, Iraq.
Email: tamara.shamil@alnoor.edu.iq

Abstract

Background: Fructosamine-3-kinase (FN3K) enzyme appears to protect proteins from nonenzymatic glycation. **Objectives:** The current study aimed to establish the activity of FN3K in serum and erythrocyte lysate. **Methods:** The activity of FN3K were estimated in (30) healthy individuals and compared to values in (35) non-diabetic myocardial infarction patients. **Results:** The results showed that there was a significant increase in the activity of enzymes in the lysate of erythrocytes, compared with the activity of enzymes in serum for both the control groups and the patients group. The results also showed a significant increase in the activity of the FN3K enzyme in the serum of patients compared to the control group. The activity of enzymes is not affected by gender for both groups. A group of biochemical variables related to myocardial infarction were measured. The result showed a negative significant relationship between the activity of the enzyme and the level of total antioxidant capacity a positive significance in glycated hemoglobin in the control group, and patients positive significance between the activity of the enzyme and the level of Zn. **Conclusion:** The activity of FN3K enzyme is affected by age, uncontrol blood glucose levels, and oxidative stress in healthy patients.

Keywords: Heart, Myocardial Infarction, Glycation, FN3K, Deglycation, AGEs.

INTRODUCTION

Myocardial Infarction (MI), is a main cause of death all over the world this term reflects the death of the cells due to a deficiency of cardiac ischemia that takes place when the blood is impeded from flowing to the heart muscle and it occurs mostly, due to accumulation of fats, cholesterol and other materials, these fat deposits that contain cholesterol are called plaques and the process of plaques accumulation is called atherosclerosis.^[1-4] Myocardial ischemia initiates inflammatory signalling, which attracts immune cells and produces reactive oxygen species as well as molecular damage.^[5-9] The risk factors of MI include age and gender, Smoking, obesity, alcohol and genetic family history.^[10] Preventing the incidence of this disease might be through controlling the diet system, pattern of life and maintaining a healthy body weight.^[11] The human body's tissues and organs contain a complex set of chemicals known as advanced glycation end-products (AGEs) their focus sharpens as they get older. Glycation fundamentally causes AGEs to develop in the human body. In this non-enzymatic process, a molecule of glucose, lipid or nucleic acids combined with an amine group from free amino acids or proteins to create a Schiff base, which then undergoes

a rearrangement to produce a fructosamine known as the Amadori product. Through additional chemical processes including oxidation and dehydration, this comparatively stable molecule can produce a variety of AGEs. These can be found in intracellular proteins, serum albumin-like plasma proteins, long-lived extracellular matrix proteins, and long-lived plasma proteins. Glycation is categorized in each of those situations as a non-enzymatic post-translational alteration of proteins^[12] this non-enzymatic alteration of protein changes not just its structure but also its biological characteristics.^[13] Glucose concentration and protein half-life are the two conventional parameters that are known to cause glycation of proteins in vivo,^[14] however, research has shown that many non-diabetic diseases are associated with higher levels of glycoprotein.^[15] In non-diabetic patients who have experienced MI, glycation is a risk factor for short-term mortality and can have a negative impact on biological systems.^[16] The deglycation process is one of the most crucial systems that repair these damages, therefore,

Address for Correspondence: Department of Chemistry, College of Science, University of Mosul, Mosul, Iraq
Email: rafadsaadun2000@uomosul.edu.iq

Submitted: 28th April, 2024

Received: 04th May, 2024

Accepted: 22nd June, 2024

Published: 04th July, 2024

Access this article online	
Quick Response Code: 	Website: www.jnsbm.org
	DOI: https://doi.org/10.4103/jnsbm.JNSBM_15_2_1

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Mohammed R R S, Abdulrahman T S. Fructosamine 3-Kinase in Erythrocytes for Myocardial Infarction Patients. J Nat Sc Biol Med 2024;15:177-182

organisms attempt to lessen the damaging consequences of the glycation process through their natural defence system as these interactions negatively affect the activities of key molecules.^[17] Fructosamine 3-Kinase (FN3K) [EC 2.7.1.171], is one of the deglycation enzymes that control the non-enzymic glycation reactions (natural defence system) inside the cells to resist the negative effects of the glycation process.^[18] The FN3K phosphorylate fructosamine compound (fructoselysin) transforms it into Fructoselysin-3-phosphate (FL3P), which is an unstable compound that decomposes spontaneously to produce the 3-Deoxyglucosone (3DG) and non-organic phosphates.^[19] The highest activity of the enzyme was spotted in the brain, heart, kidneys and muscles.^[20] Elevated levels of advanced glycation endproducts (AGE) increase the risk of cardiovascular disease comorbidity and mortality, the FN3K enzyme reduces risk by lowering AGE levels.^[21] Early studies indicate that FN3K might play a vital role in reducing the formation of Advanced glycation end products (AGEs) which is related to the damage of various tissues including the heart.^[22] The research aims to study the activity of FN3K in healthy people from two different sources serum and red blood cells, in addition to determining the activity of enzyme FN3K in patients with MI and its relationship to occurrence and development of disease.

MATERIALS AND METHODS

The study was conducted using human blood specimens and samples collected from April to June 2023 in cooperation with the Mosul Center for Cardiac Medicine and Surgery and Blood Bank in Mosul City. The groups were distributed as follows:

Control group: 30 specimens were collected from healthy persons; (15) of them from males and (15) of females whose ages ranged from 40 to 70 years old.

MI Group: 35 specimens of blood were taken from individuals who suffer from MI. The specimens included (16) males and (19) females with ages ranging from 40 to 70 years old.

Erythrocytes Separation: To separate erythrocytes from other components of blood, firstly uncoagulated blood is obtained as the blood taken from the person is put in a tube that contains the anticoagulant ethylene di-amin tetra acetic acid (EDTA).

^[23] After that red blood cells are separated the uncoagulated

blood is put in the centrifuge with a speed of (3000Xg) for ten minutes to ensure obtaining the red blood cells only. The plasma and the white layer are removed and the red cells are washed with sodium chloride (0.9%) three times.^[24]

Hemolysis erythrocytes preparation: The erythrocytes hemolysis results from the breaking of the red blood cells by Osmotic lysis. One volume of erythrocytes was prepared in the previous paragraph and they were incubated in (4°C for at least 4 hours. After that, the erythrocytes are put in the centrifuge for 20 minutes at a speed of (9000×g) for the purpose of sedimentation of the membranes of red blood cells.^[25]

Fructosamine-3kinase enzyme measured using the ELISA technique as per manufacturer instruction using Kit supplied by Sunlong company (China).^[26] Iron and zinc measured atomic spectrophotometry technique as per manufacturer instruction using Kit supplied by the Solarbio Company(Chinese).^[27,28] Total Antioxidant Capacity using the spectrophotometry technique and the analysis kit manufactured by Biohermes company.^[29] The Glycated haemoglobin HbA1c and activity of Creatine Kinase enzyme was estimated using the analysis kit manufactured by Roche German Company using the Cobas device.^[27,30] Moreover, the concentration of glucose, total cholesterol, Triglyceride, Low-density lipoprotein cholesterol. High-density lipoprotein cholesterol and lactate dehydrogenase (LDH) were estimated using the analysis kit made by BioLabo company using a spectrophotometer.^[31]

RESULT

Activity of FN3K enzyme was estimated in erythrocytes lysate in MI and control groups, results showed a very high significant increase in activity of FN3K in the MI group ($590 \pm 10.6 \text{ ng/l}$) at $P \leq 0.001$ compared to the control group ($387.7 \pm 3.2 \text{ ng/l}$) as shown in Figure 1 and activity of FN3K not affected by gender for both groups in erythrocytes lysate. The activity of FN3K enzyme also was estimated in serum in MI and control groups, results showed a very high significant increase in the activity of FN3K in MI patients ($263.5 \pm 2.17 \text{ ng/l}$) at $P \leq 0.001$ compared to the control group (182.3 ± 7.36) as shown in Figure 2 and activity of FN3K not affected by gender for both groups in serum, The results indicated a highly significant increase in activity of the enzyme in erythrocytes lysate compared to serum




Figure 1: Activity of FN3K in Erythrocytes Lysate and Serum of Control and MI Groups. Data Expressed as mean±SD, *Indicates Significantly Higher at $p < 0.05$ Using Independent Sample t-test. eFN3K=Erythrocyte Fructosamine 3-kinase, sFN3K=Serum Fructosamine 3-kinase, MI=Myocardial Infarction.

Results of the research indicated that there was an increase in levels of FBS, HbA1c and a very high significant increase in activity of CK and LDH in the MI group compared with the control group and decreased levels of TAC and Zn in the MI group also, increase in levels of

Fe in patients compared with control group, results show increase in TC, TG, LDL-C, VLDL-C, TG on HDL, TG on LDL and decrease in HDL in MI group compared with control group (Table 1).

Table 1: Results of Some Variables in MI Patients Compared to the Control Group.

Variables Groups	Control Group (Mean±SE)	MI (Mean±SE)
FBS(mg/dl)	94.8±2.3	117.2±2.2
HbA1c	4.8±0.1	6.7±0.9
CK(U/L)	11.06±0.3	40.17±2.1
LDH(U/L)	186.36±7.4	354.25±7.5
TAC(μmol/ml)	1.31±0.4	0.94±0.8
Zn(μg/dl)	91.03±1.3	44.4±1.2
Fe(μg/dl)	121.8±1.1	189.2±1.6
TC(mg/dl)	130.9±3.2	190.6±1.6
TG(mg/dl)	144.3±4.9	198.6±2.6
HDL-C	41.7±0.2	30.2±1.09
LDL-C	88.9±5.8	134.1±1.3
VLDL-C	27.1±9.09	37.05±1.03
TG on HDL	3.4±0.1	6.86±0.2
TG on LDL	1.9±0.1	1.48±0.02

The result shows there was an inverse relationship between the activity of FN3K and HbA1c and direct relationship between TAC and FN3K activity in the MI group and a highly significant inverse relationship between Zn and FN3K in the control group (Table 2).

Table 2: Linear Correlation Coefficients of Some Variables with FN3K in the MI Group.

Parameters	Groups	r
HbA1c	MI	-0.74
TCA	FN3K	0.58
Zn	Control	-0.44

DISCUSSION

The present study demonstrated an increase in the activity of the FN3K enzyme in erythrocytes lysate in both groups, control and MI. This is consistent with the researchers' findings.^[32] The reason can be attributed to enzyme activity is associated more with intracellular glycation than with plasma protein glycation. This would lead us to suppose that the main effect of FN3K is to deglycate intracellular proteins.^[33] The results also showed a significant increase in enzyme activity in the MI group compared to the control group. The reason can be attributed to concentrations of glycated haemoglobin being dramatically elevated in MI patients, it appears on the borderline in comparison to healthy subjects. Results also demonstrated that no significant correlation between blood sugar with glycated haemoglobin. In the line with this finding, Gosavi *et al.*^[34] reported an increased level of Hb_{A1c} in non-diabetic with acute MI.^[34] The glycation induce As glycation can jeopardize physiological pathways and is a destructive biomarker for short-term mortality following acute MI in non-diabetic patients.^[35] Moreover,

glycation reciprocally correlated with lipid peroxidation markers.^[36] Redox imbalances encourages glycation and potentiates induction of MI perhaps in non-diabetic patients providing clear evidence of glycation role in the precipitation of cardiovascular ailments due to presence of some biogenic factors, perhaps the activity of FN3K.^[37] Data represented elevated blood sugar level was not high and was within acceptable limits in patients with MI, and the reason is attributed to the fact that increased glucose in serum increases the risk of heart disease including MI, as a result of disrupting the normal endothelial function of blood vessels by oxidative stress that increase in thickness of arteries which leads to death or damage to the heart muscle.^[38] The results also showed that there was a very high significant increase in the activity of both CK and LDH enzyme in MI patients compared to the control group the reason for the increase in two enzymes is due to damage or defect in the heart muscle and this is consistent with Harahap and Margata^[39], a very high significant decrease in concentration of total antioxidants capacity(TAC) in patients and this decrease reduces the important role of TAC as an antioxidant in protecting the heart muscle from lipid peroxidation products^[40] results also showed that there was a decrease in the level of Zn in MI compared to the control group, the decrease in zinc reduces its role as an antioxidant and then increases oxidative stress and inflammation, which causes damage to the heart muscle^[28,41] and a very high significant increase in the level of iron in serum of patients with M compared with control group, and this is consistent with Ahmed *et al.*^[42] where the level of iron increases in patients which leads to its accumulation in the walls of blood vessels. The results in Table 1 also showed a very high significant increase in concentration of TC, TG, LDL-C, and VLDL-C and

a very high significant decrease in HDL concentration in the patient group compared to the control group, this is consistent with Noreen *et al.*^[43], where the excessive concentration of cholesterol and fats in the blood leads to an imbalance in the blood flow to and from the heart, and increase ratio TG/HDL-C and TG/LDL-C in MI is a potential risk factor for prediabetes and associated with insulin resistance and cardiovascular disease.^[44,45]

CONCLUSION

The present study concluded that fructosamine 3-kinase in erythrocytes served as a diagnostic tool for diagnosis and follow-up of patients with myocardial infarction patients.

REFERENCES

1. Nurkina D, Baimuratova M, Zhussupbekova L, Kodaspayev A, Alimbayeva S. Assessment of Risk Factors of Myocardial Infarction in Young Persons. *Georgian Med News*. 2023; (334): 71-77. Available from: <https://europepmc.org/article/med/36864796>.
2. Ismail HY, Al-Sultan SA. Association of coronary atherosclerosis with *Stutzerimonas stutzeri* strains (HaSa1, 2, 3, and 4) biofilm-forming bacteria. *Medicinski časopis*. 2023; 57(2): 47-52. doi: <https://doi.org/10.5937/mckg57-44962>.
3. Chen J, Gao F, Liu W. Atrial cardiopathy in embolic stroke of undetermined source. *Brain Behav*. 2021; 11(6): e02160. doi: <https://doi.org/10.1002/brb3.2160>.
4. Khattab MH, Shahwan MJ, Hassan N, Jairoun AA. Abnormal High-sensitivity C-reactive Protein is Associated with an Increased Risk of Cardiovascular Disease and Renal Dysfunction among Patients Diagnosed with Type 2 Diabetes Mellitus in Palestine. *Rev Diabet Stud*. 2022; 18(1): 27-33. doi: <https://doi.org/10.1900/rds.2022.18.27>.
5. Jabber HN, Charfeddine B, Abbas HJ. Evaluation of FGF23, C-reactive Protein and Lipid Profile as Predictors for Cardiovascular Diseases in Patients with Type 2 Diabetes. *Rev Diabet Stud*. 2023; 19(3): 145-57. doi: <https://doi.org/10.1900/RDS.2023.19.145>.
6. Jabber HN, Charfeddine B, Abbas HJ. Evaluation of Tumor Necrosis Factor Alpha, Insulin, glucose, HbA1c% and HOMA-IR as Predictors for Cardiovascular Diseases in Patients with Type 2 Diabetes. *Pharmacogn J*. 2024; 16(1): 195-201. doi: <https://doi.org/10.5530/pj.2024.16.27>.
7. Sihning EJT, Untari NKSD, Pia DM. Unlocking the Potential of Stingray (*Dasyatis sephen*) Extract: A Novel Investigation into EPA and DHA Effects on Lipid Metabolism in High-Fat Diet-Fed Wistar Rats. *Pharmacogn J*. 2024; 16(1): 28-36. doi: <https://doi.org/10.5530/pj.2024.16.4>.
8. Aswar UM, Nimse SR, Thakurdesai PA. Androgenic Efficacy and Mechanism of Glycosides-Based Standardized Fenugreek Seeds Extract Through Aromatase And 5-Alpha Reductase Inhibition. *Pharmacogn J*. 2024; 16(1): 9-19. doi: <https://doi.org/10.5530/pj.2024.16.2>.
9. Yaakoubi W, Taamallah K, Haggui A, Hajlaoui N, Fehri W. Prognostic contribution of two-dimensional left atrial strain in patients with asymptomatic mitral stenosis in the Tunisian population. *Medicinski časopis*. 2022; 56(3): 95-100. doi: <https://doi.org/10.5937/mckg56-41404>.
10. Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016. *Circulation*. 2019; 139(8): 1025-35. doi: <https://doi.org/10.1161/circulationaha.118.035550>.
11. Feng S, Wang H, Liu J, Aa J, Zhou F, Wang G. Multi-dimensional roles of ketone bodies in cancer biology: Opportunities for cancer therapy. *Pharmacol Res*. 2019; 150: 104500. doi: <https://doi.org/10.1016/j.phrs.2019.104500>.
12. Rescalli A, Varoni EM, Cellesi F, Cerveri P. Analytical Challenges in Diabetes Management: Towards Glycated Albumin Point-of-Care Detection. *Biosensors (Basel)*. 2022; 12(9): 687. doi: <https://doi.org/10.3390/bios12090687>.
13. Harmel R, Fiedler D. Features and regulation of non-enzymatic post-translational modifications. *Nat Chem Biol*. 2018; 14(3): 244-52. doi: <https://doi.org/10.1038/nchembio.2575>.
14. Rabbani N, Ashour A, Thornalley PJ. Mass spectrometric determination of early and advanced glycation in biology. *Glycoconj J*. 2016; 33(4): 553-68. doi: <https://doi.org/10.1007/s10719-016-9709-8>.
15. Barchetta I, Ceccarelli V, Cimini FA, et al. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. *J Endocrinol Invest*. 2019; 42(5): 513-20. doi: <https://doi.org/10.1007/s40618-018-0941-x>.
16. Mi SH, Su G, Yang HX, Zhou Y, Tian L, Zhang T, Tao H. Comparison of in-hospital glycemic variability and admission blood glucose in predicting short-term outcomes in non-diabetes patients with ST elevation myocardial infarction underwent percutaneous coronary intervention. *Diabetol Metab Syndr*. 2017; 9: 20. doi: <https://doi.org/10.1186/s13098-017-0217-1>.
17. Shrestha S, Katiyar S, Sanz-Rodriguez CE, et al. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. *Sci Signal*. 2020; 13(639): eaax6313. doi: <https://doi.org/10.1126/scisignal.aax6313>.
18. Szwergold B. A Hypothesis: Fructosamine-3-Kinase-Related-Protein (FN3KRP) Catalyzes Deglycation of Maillard Intermediates Directly Downstream from Fructosamines. *Rejuvenation Res*. 2021; 24(4): 310-18. doi: <https://doi.org/10.1089/rej.2021.0009>.
19. Yousefi T, Pasha ARG, Kamrani G, et al. Evaluation of Fructosamine 3-kinase and Glyoxalase 1 activity in normal and breast cancer tissues. *Biomedicine (Taipei)*. 2021; 11(3): 15-22. doi: <https://doi.org/10.37796/2211-8039.1130>.

20. Delplanque J, Delpierre G, Oppendoes FR, Van Schaftingen E. Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein. *J Biol Chem*. 2004; 279(45): 46606-13. doi: <https://doi.org/10.1074/jbc.m407678200>.
21. Simm A. Protein glycation during aging and in cardiovascular disease. *J Proteomics*. 2013; 92: 248-59. doi: <https://doi.org/10.1016/j.jprot.2013.05.012>.
22. De Decker I, Notebaert M, Speeckaert MM, et al. Enzymatic Deglycation of Damaged Skin by Means of Combined Treatment of Fructosamine-3-Kinase and Fructosyl-Amino Acid Oxidase. *Int J Mol Sci*. 2023; 24(10): 8981. doi: <https://doi.org/10.3390/ijms24108981>.
23. Nieuwland R, Siljander PR. A beginner's guide to study extracellular vesicles in human blood plasma and serum. *J Extracell Vesicles*. 2024; 13(1): e12400. doi: <https://doi.org/10.1002/jev2.12400>.
24. Beutler E, Blume KG, Kaplan JC, Löhr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. *Br J Haematol*. 1977; 35(2): 331-40. doi: <https://doi.org/10.1111/j.1365-2141.1977.tb00589.x>.
25. Price NC, Stevens L. Enzymes in the Cell. In: *Fundamentals of Enzymology*. 2nd ed. New York: Oxford University Press; 1989:365-66.
26. Abdulrahman T, Mohammed R. Assessment of Fructosamine 3-kinase in Type 2 Diabetic Patients and Its Relation to Some Biochemical Variables. *Journal of Life and Bio Sciences Research*. 2023; 4(1): 6-9. doi: <https://doi.org/10.38094/jlbrs40187>.
27. Younis HY, Thanoon IA, Fadhil NN, Merkhani MM. Effect of zinc as an add-on to metformin therapy on glycemic control, serum insulin, and c-peptide levels and insulin resistance in type 2 diabetes mellitus patient. *Research Journal of Pharmacy and Technology*. 2022; 15(3): 1184-88. doi: <https://doi.org/10.52711/0974-360X.2022.00198>.
28. Younis HY, Thanoon IA, Fadhil NN, Merkhani MM. Effect of zinc as an add on to metformin therapy on serum lipid profile and uric acid in type 2 diabetes mellitus patients. *Current Topics in Pharmacology*. 2021; 25: 53-59. Available from: <https://www.cabidigitallibrary.org/doi/full/10.5555/20220091647>.
29. Abdulqader SW, Faisal IM, Saeed MG, Merkhani MM. Fluvoxamine Suppressed Oxidative Stress associated with Tissue Erosion. *Research Journal of Pharmacy and Technology*. 2022; 15(2): 819-24. doi: <https://doi.org/10.52711/0974-360X.2022.00136>.
30. Brancaccio P, Maffulli N, Limongelli FM. Creatine kinase monitoring in sport medicine. *Br Med Bull*. 2007; 81-82: 209-30. doi: <https://doi.org/10.1093/bmb/ldm014>.
31. Hamed ZS, Abed RR, Almashhadany MS, Merkhani MM. Effects of Hypericum perforatum on serum lipid vascular systems in mice. *Iraqi Journal of Veterinary Sciences*. 2022; 36(2): 525-30. doi: <https://doi.org/10.33899/ijvs.2021.130708.1868>.
32. Avemaria F, Carrera P, Lapolla A, et al. Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients. *Clin Chem Lab Med*. 2015; 53(9): 1315-20. doi: <https://doi.org/10.1515/cclm-2015-0207>.
33. Alderawi AS. The role of a deglycating enzyme 'fructosamine-3-kinase' in diabetes and COPD. Doctoral Dissertation, University of Wolverhampton; 2017. Available from: <http://hdl.handle.net/2436/620816>.
34. Gosavi S, Karande S, Raut K. HbA1c: A Marker for Severity of Acute Myocardial Infarction. *International Archives of Integrated Medicine*. 2016; 3(5): 89-93. Available from: https://www.iaimjournal.com/storage/2016/05/iaim_2016_0305_15.pdf.
35. Parthibane V, Selvaraj N, Sathiyapriya V, Bobby Z, Rajappa M. Increased non-enzymatic glycation of plasma proteins and hemoglobin in non-diabetic patients with acute myocardial infarction (MI). *J Clin Diagn Res*. 2013; 7(12): 2692-3. doi: <https://doi.org/10.7860/jcdr/2013/7331.3884>.
36. Selvaraj N, Bobby Z, Sathiyapriya V. Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. *Clin Chim Acta*. 2006; 366(1-2): 190-5. doi: <https://doi.org/10.1016/j.cca.2005.10.002>.
37. Fazly Bazzaz BS, Malaekheh-Nikouei B, Roohbakhsh A, Arabi L. The 15th Iranian National Congress of Biochemistry & 6th International Congress of Biochemistry and Molecular Biology. *Iran J Basic Med Sci*. 2019; 22: 1-152. doi: <https://doi.org/10.22038/ijbms.2019.12264>.
38. Lee G, Choi S, Kim K, et al. Association of Hemoglobin Concentration and Its Change With Cardiovascular and All-Cause Mortality. *J Am Heart Assoc*. 2018; 7(3): e007723. doi: <https://doi.org/10.1161/jaha.117.007723>.
39. Harahap U, Margata L. The Significance of Troponin and Ck-Mb in Association with Q-Wave Myocardial Infarction. *Indonesian Journal of Pharmaceutical and Clinical Research*. 2018; 1(1): 11-17. doi: <https://doi.org/10.32734/idjpcr.v1i1.199>.
40. Hassan GF, Khairy BS, Mohammed NY, Mohammed IJ, Sarhat ER. Evaluation of Salivary Oxidative Stress Marker (Lipid Peroxidation), and Non-Enzymatic Antioxidants (Vitamin C and Vitamin E) in Patients with Acute Myocardial Infarction. *Tikrit Journal for Dental Sciences*. 2019; 7(1): 20-26. Available from: <https://www.iasj.net/iasj/article/177225>.
41. Choi S, Liu X, Pan Z. Zinc deficiency and cellular oxidative stress: prognostic implications in cardiovascular diseases. *Acta Pharmacol Sin*. 2018; 39(7): 1120-32. doi: <https://doi.org/10.1038/aps.2018.25>.
42. Ahmed WBH, Abdalla RE, Mahjaf GM, Hassan HA, Mohamed TMA, Hamad MNM. Evaluation of Iron Profile among Ischemic Heart Disease Patients in Shendi City, Sudan. *SAR J Med*. 2022; 3(3): 36-40. doi: <https://doi.org/10.36346/sarjm.2022.v03i03.003>.

43. Noreen S, Rehman HU, Tufail T, Badar Ul Ain H, Awuchi CG. Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions. *Food Sci Nutr*. 2023; 11(6): 2620-30. doi: <https://doi.org/10.1002/fsn3.3250>.
44. Ouchi G, Komiya I, Taira S, Wakugami T, Ohya Y. Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients. *Lipids Health Dis*. 2022; 21(1): 4. doi: <https://doi.org/10.1186/s12944-021-01612-8>.
45. Borrayo G, Basurto L, González-Escudero E, et al. TG/HDL-C Ratio as Cardio-metabolic Biomarker Even in Normal Weight Women. *Acta Endocrinol (Buchar)*. 2018; 14(2): 261-67. doi: <https://doi.org/10.4183/aeb.2018.261>.